Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on TG Therapeutics (TGTX – Research Report). The company’s shares opened today at $14.30.

According to TipRanks, Stranahan is a 3-star analyst with an average return of 5.0% and a 54.32% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Krystal Biotech, and Revolution Medicines.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TG Therapeutics with a $28.00 average price target.

Based on TG Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $43.97 million and a GAAP net loss of $14.42 million. In comparison, last year the company earned a revenue of $81 thousand and had a GAAP net loss of $52.99 million

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TGTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TG Therapeutics (TGTX) Company Description:

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.